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Rate Ratio (IRR) - 1.28, 95% CI:1.09 -1.51) higher rate for number of visits to the office
basedphysicianswhencompared tomales. Blackshad31% (IRR-0.69, 95%CI:0.53-0.89)
lower rate of ambulatory care utilization when compared toWhites. Publicly insured
individuals had 66% (IRR-1.66, 95%CI:1.26-2.18) higher rate of ambulatory care utiliza-
tionwhereas uninsured individuals have 37% (IRR-0.63, 95%CI:0.40-0.99) lower rate of
ambulatory care utilization than the ADHD patients with private health insurance.
CONCLUSIONS: Gender, and racial disparities exist in ambulatory care utilization
among ADHD patients. Providing some kind of health insurance coveragemight help
in reducing thesedisparities andoptimizingambulatory careutilizationamongADHD
patients.
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TRENDS IN PREVALENCE OF ADHD DRUG TREATMENT IN THE NETHERLANDS
FROM 2000 UNTIL 2010
Mehlkopf L1, Houweling LMA2, Heerdink ER1, Penning FJA2
1Utrecht University, Utrecht, The Netherlands, 2PHARMO Institute for Drug Outcomes Research,
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OBJECTIVES: ADHD is a major concern since it is one of the most commonmental
disorders affecting children and adolescents. The prevalence of ADHD has been
reported to be increasing in the past decade. We assessed the trends in prevalence
of ADHD drug use in the Netherlands from 2000 until 2010. METHODS: From the
PHARMO database, including amongst others, drug dispensing records of approx-
imately 3.2 million inhabitants in The Netherlands, we selected patients with at
least one dispensing of ADHDmedication includingmethylphenidate, dexamphet-
amine and atomoxetine, between 2000 and 2010. For each calendar year, patients
were counted as prevalent ADHDdrug users if they received a dispensing for ADHD
treatment in the respective calendar year. The number of ADHD drug users in
PHARMOwas divided by the number of residents in PHARMO andmultiplied by the
number of inhabitants in the Netherlands, standardized for age and gender. Re-
sults were stratified by age groups and gender. RESULTS: The prevalence of ADHD
drug treatment among males was higher than among femals. From 2000 to 2010,
the prevalence among children (0-12 years) has increased 2.6-fold in males (from
158 to 410 per 10,000) and 4.5-fold in females (from 27 - 119 per 10,000). The prev-
alence among adolescents (13-18 years) has increased 4.0-fold in males (170 - 675
per 10,000) and 7.4-fold in females (27 - 200 per 10,000). The prevalence among
adults (19 years) has increased 8.2-fold in males (from 8 - 63 per 10,000) and
10.1-fold in females (from 4 - 43 per 10,000). CONCLUSIONS: This study provides a
comprehensive overview of trends in prevalence of ADHD drug treatment in The
Netherlands. Both in males and females, a continuous increase in prevalence was
observed.
PMH16
MALE/FEMALE INCIDENCE RATIO OF ADHD DRUG TREATMENT IN THE
NETHERLANDS FROM 2000 UNTIL 2010
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OBJECTIVES: ADHD has become a much debated topic in the last few years. More
attention and awareness for ADHD has led to an increase in incidence. Especially
awareness for the subtype of ADHD where patients, mostly females, demonstrate
predominantly inattentive symptoms, has increased. We determined the male/
female incidence ratio of ADHD drug treatment in the Netherlands from 2000 until
2010. METHODS: From the PHARMO database, including amongst others, drug
dispensing records of approximately 3.2million inhabitants in theNetherlands, we
selected patients with a first dispensing of ADHD medication including methyl-
phenidate, atomoxetine and dexamphetamine in the period 2000-2010. For each
calendar year, the male/female incidence ratio of ADHD drug use was determined
by dividing the incidence among males by the incidence among females. Results
were stratified by age groups. RESULTS:Overall, themale/female incidence ratio of
ADHD drug treatment decreased from 3.4:1 in 2000 to 1.6:1 in 2010, meaning a
growing proportion of female patients. The largest decrease in the male/female
ratio was observed among adolescents (13-18 years: from 4.5:1 in 2000 to 1.6:1 in
2010), followed by 9-12 year-olds (from5.5:1 in 2000 - 2.7:1 in 2010) and 0-8 year-olds
(from 6.2:1 in 2000 - 3.5:1 in 2010). Among adults and seniors this ratio fluctuated
from 0.9:1 to 2.1:1. Although the incidence among females has increasedmore over
the years, the incidence among males remained higher throughout the study
period. CONCLUSIONS: This study shows that the proportion of female patients
starting ADHD drug treatment is increasing. This in line with the increased aware-
ness of ADHD among females.
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OBESITY AND RISK OF DEPRESSION/ANXIETY IN CHILDREN AND
ADOLESCENTS: A MEDICAL EXPENDITURE PANEL SURVEY STUDY
Bhattacharya R1, Aparasu RR2, Rajan SS2, Chen H2
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OBJECTIVES: To examine the association between obesity and depression/anxiety
and related expenditures in children and adolescents.METHODS: Data from Med-
ical Expenditure Panel Survey (MEPS) longitudinal panels 9, 10, 11 and 12 were
combined to analyze the risk of depression/anxiety in a cohort of children and
adolescents (aged 6-17 years). Incident depression/anxiety was identified during
one year follow-up using Clinical Classification Codes (CCCODEX) for depression
(657) and anxiety (651) or by Multum Lexicon Therapeutic Classification Codes for
anti-anxiety (067) or antidepressant (249) drugs. Body Mass Index (BMI)-for-age 
85th-percentile of the 2000 sex-specific Center for Disease Control (CDC) BMI-for-
age growth charts, was considered obese/overweight. Due to possibility of reverse
causality, instrument variable model with the BMI of mother and its square as
exogenous measures for overweight status was evaluated. Two stage analyses,
however, revealed that overweight status was not an endogenous variable. Conse-
quently, association between obesity and depression/anxiety was evaluated using
multivariate logistic regression. The risk of increased depression/anxiety expendi-
tures was examined using a two part expenditure model was used. RESULTS: An
estimated 3.67 million (95% Confidence Interval (CI): 3.47-3.87) were obese/over-
weight in national weighted sample 10.34 million children and adolescents. The
incidence depression/anxiety among obese/overweight and non-overwight chil-
dren was 0.95and 1.75%, respectively. Multivariable analysis of a nationally repre-
sentative sample of children and adolescents indicated no significant association
between obese/overweight status and development of depression/anxiety [Ad-
justed Odds Ratio (AOR):0.65; 95% Confidence Interval (CI): 0.65-1.37]. In addition,
there was no increased f risk of depression/anxiety related expenditure (AOR: 1.39;
95% CI: 0.67-2.90), nor the risk of an increased amount of expenditure (t-statistic:
-0.41; P-value: 0.19) due to obesity/overweight. CONCLUSIONS: Obese/overweight
children and adolescents in this nationally representative community sample did
not have an increased likelihood of depression/anxiety. Thus, obese/overweight
children and adolescents may not always suffer from psychological distress.
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FACTORS ASSOCIATED WITH REAL-WORLD INPATIENT USE OF LONG-ACTING
ATYPICAL ANTIPSYCHOTICS
Fastenau J1, Campbell RS2, Nathanson BH3, Haidar T2, Yi J2, Wade R2
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OBJECTIVES: Long-acting therapy (LAT) formulations of atypical antipsychotics
(AAPs) remove the need for dailymedication in the treatment of schizophrenia and
may improve outcomes. Little is known about LAT AAP use during inpatient ad-
missions. This study identifies factors associated with LAT AAP use among inpa-
tients with schizophrenia. METHODS: A retrospective analysis (2007-2010) of the
Health Facts® database (Cerner Corp., Kansas City, MO) identified adult patients
with a primary discharge diagnosis of schizophrenia and1 order for AAP. Factors
examined included demographic, clinical, and treatment setting characteristics. A
bootstrapping algorithmwithmultilevel (hierarchical) logistic regressionwas used
to identify factors most strongly associated with LAT AAP exposure. RESULTS: A
total of 3230 admissions met inclusion criteria; 217 had LAT AAP exposure. Before
regression adjustment, key factors with a significantly greater likelihood of LAT
AAP use included receiving oral risperidone (85.3% vs 35.0%, p0.001) and being
treated in a facility with500 beds (48.9% vs 31.5%, p0.001). Negative associations
included Caucasian race (47.9% vs 55.4%, p0.033), receiving most other oral AAPs
(varies by agent), and being treated in a facility with 500 beds (varies by categor-
ical size). Factors not significantly associatedwith LATAAP use included age, use of
first-generation antipsychotics, urgent admission, and treatment in a teaching fa-
cility. The regression model had good discrimination (c-statistic  0.85); factors
associated with a greater likelihood of LAT AAP exposure were male gender
(OR1.58, p0.005), diagnosis of chronic respiratory conditions (OR1.64, p0.014),
affective disorders not meeting criteria for full mood disorder (OR1.95, p0.004),
and oral risperidone (OR11.05, p0.001). Patients using olanzapine (OR0.64,
p0.057) or antidepressants (OR0.75, p0.065) trended toward not receiving LAT
AAP. CONCLUSIONS: LAT AAP use in the inpatient setting was related to gender,
certain chronic conditions, specific AAP and antidepressant use, and facility size.
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COMBINATION UTILIZATION PATTERNS AND TREATMENT PREDICTORS IN
ADHD IN A COMMERCIALLY INSURED POPULATION
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OBJECTIVES: Several stimulant and non-stimulant medications are indicated and
used alone or in combination to treat attention deficit hyperactivity disorder
(ADHD). Little is known about polypharmacy prevalence and predictors in this
population. The objective of this analysis was to describe ADHD medication utili-
zation patterns focusing on combination versus monotherapy.METHODS: Health
insurance claims from Thomson Reuters MarketScan Commercial Database were ana-
lyzed for patients with an ADHD diagnosis (ICD-9 314.0x). Patients included were
age6 as of January 2010, continuously enrolled July 2009 through December 2010,
and with a 2010 ADHD medication claim. Medication utilization was measured at
the patient-month level during 2010. Generalized-estimating equations were used
to account for within-patient correlation between months. Demographic and clin-
ical predictors were explored with atomoxetine (ATX), long-acting stimulants
(LAS), and alpha-2-adrenergic agents (A2A). RESULTS: ADHD patients (n268,172)
were primarily age 6-17 years old (57.9%) andmale (61.2%). ADHDwith hyperactiv-
itywas present in 14.2%.Of all treatment-months, 10.3%were combination therapy
(more than one ADHD medication class in same month). Short-acting stimulants
and A2A agents had the highest combination use (45.3%, 54.0% respectively). ATX,
LAS, intermediate-acting stimulants, and prodrug stimulants had the lowest per-
centage combination use (17.9%, 13.6%, 21.8%, 9.9% respectively), ATX combination
therapy was less in older patients (age 18 adjusted odds ratios [AOR] between
0.332-0.829), LAS agents were more frequently used (ages 18-44 AOR 1.079-1.457)
and A2A had no association (age 25 AOR 0.699-1.083). Females were less likely to
use combination therapy. Hyperactivity was associated with combination therapy
in all three models. Tics/Tourettes was associated with combination therapy for
ATX and LAS. CONCLUSIONS: Combination therapy rates differed by medication
class, as did the demographic and clinical characteristics that significantly pre-
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dicted combination therapy with ATX, LAS, and A2As. This suggests these medi-
cations may be used differently in clinical practice.
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OBJECTIVES: Bipolar disorder (BD) is associated with a high burden on healthcare
resources. A secondary objective of the Wide AmbispectiVE study of the clinical
management and burden of bipolar disorder (WAVE-bd) was to assess healthcare
resource utilization among BD patients. METHODS: Multinational, multicenter,
non-interventional, cohort study of patients diagnosed with BD-I/BD-II with 1
mood episode in the preceding 12 months (retrospective data collection) followed
by a minimum 9 months’ prospective follow-up. Study population was represen-
tative of BD populations from 8 European and 2 Latin American countries. Multi-
variate analyses determined factors associated with higher incidence of resource
use (number of visits per year), measured by parameter estimates (ParEst [95% CI])
0. RESULTS: Multivariate analyses included 2,896 patients. Factors associated
with a higher incidence of hospitalizations included: psychotic symptoms during
the study index episode (0.08 [0.02; 0.14]); a higher number of previous hospitaliza-
tions (0.04 [0.03; 0.04]); receiving anxiolytics during the study index episode (0.12
[0.06; 0.17]); enrolment in hospital settings (0.13 [0.03; 0.23]). The incidence of emer-
gency room visits was increased in patients with: rapid cycling (0.13 [0.06; 0.19]); a
history of suicide attempts (0.08 [0.02; 0.14]); a higher number of previous hospital-
izations (0.01 [0.01; 0.02]). The incidence of programmed psychiatrist visits was
increased in patients: with rapid cycling (0.90 [0.36; 1.44]); with a higher number of
previous hospitalizations (0.11 [0.06; 0.16]); enrolled in private practices (1.31 [0.07;
2.55]); receiving antipsychotics during study index event (0.81 [0.37; 1.25]). Overall,
clinical factors associated with higher incidence of resource use included: rapid
cycling (2.22 [0.84; 3.61]); co-morbidity of thyroid disease (2.21 [0.49; 3.92]); a higher
number of previous hospitalizations (0.25 [0.12; 0.38]); receiving antipsychotics dur-
ing the study index episode (1.63 [0.50; 2.76]). CONCLUSIONS: Several clinical fac-
tors are associated with higher resource utilization in BD patients. These factors
could aid in identification of high-risk patients.
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A SYSTEMATIC REVIEW OF EFFECT OF ANTIPSYCHOTIC AGENTS ON
MORTALITY IN SCHIZOPHRENIA
Kamble PS1, Mullen PD2, VonVille H2, Aparasu RR1
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OBJECTIVES: Mortality among schizophrenia patients is higher than the general
population. Antipsychotics are the mainstay of schizophrenia treatment but have
been linked to life threatening adverse events. Therefore the objective of the study
was to systematically review available literature examining the risk of mortality
associated with antipsychotic use among schizophrenia patients.METHODS: Sys-
tematic review of English literature was conducted in MEDLINE, PubMed,
PsychInfo, EMBASE, Cochrane databases, and IPA from 1966 to October 2011 using
nine element eligibility criteria to identify studies examining the association be-
tween antipsychotic use and mortality. The primary inclusion criteria involved
diagnosis of schizophrenia, exposure to antipsychotics, at least one year follow up,
and ascertainment ofmortality. Findings from case-control, cohort, and controlled
trial studies were abstracted for evidence table preparation and possible
meta-analyses. RESULTS: Overall sixteen studies were included after employing
nine element eligibility criteria. The studies were heterogeneous in terms of study
designs; follow up period, and control of selection bias and confounding. Conse-
quently meta-analysis was not conducted. Nine out of sixteen studies concluded
increased risk of mortality among antipsychotic users compared to non-users.
Three out of four studies examining the antipsychotic polypharmacy found signif-
icant positive effect onmortality. One out of two studies examining the compliance
with antipsychotics found negative effect on mortality. One out of two studies
examining association of antipsychotic dosages found significant association with
increased mortality. One study ascertained stable association with antipsychotic
treatment intensity and increased cardiovascular mortality while other found no
significant association. The follow up period varied from 1 to 17 years. Prospective
studies controlled for lifestyle related factors while retrospective studies for some
comorbidities and co-medications. CONCLUSIONS: Literature review revealed that
antipsychotic use and antipsychotic polypharmacy increased the risk of mortality.
Well designed observational studies accounting for selection bias and confounding
are needed to establish the relationship.
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CORRELATES OF DROPOUT FROM COMMUNITY-BASED METHADONE
MAINTENANCE TREATMENT PROGRAM IN INDONESIA
Hikmayani NH, Rahardjo SS, Doewes M
Sebelas Maret University, Solo, Central Java, Indonesia
OBJECTIVES:To study factors associatedwith risk of dropout amongheroin addicts
enrolled in a community-based methadone maintenance treatment (MMT) clinic
in Solo, Central Java, Indonesia. METHODS: This was an ambi-directional cohort
study. The index date was patients’ first entry identified from medical records.
Patients enrolled from September 2009 were followed up until departure from the
clinic or otherwise censored in May 2011. Other data collected were methadone
doses, risk behaviour, and sociodemographic characteristics. Kaplan-Meier
method was used to estimate retention rate and Cox proportional hazard regres-
sions were used to determine factors associated with dropout from treatment.
RESULTS: Ninety-eight patients aged 31.6 years old on average contributed to
14,804 person-days of folllowup. The retention ratewas 24.2%after 21monthswith
median retention time of 78 days. The median and maximum dose were 43.1 mg
and 150 mg, respectively. Multivariate analysis showed that methadone dose be-
low 80 mg (HR2.4, p0.014, 95% CI1.2-4.8) and absence of family support
(HR5.0, p0.001, 95% CI2.4-10.6) were significantly associated with risk of drop-
out. HIV status, overdose history, criminal record, duration of addiction, distance
from clinic, marital status, and employment were not statistically significant pre-
dictors of dropout. CONCLUSIONS: Despite high prevalence of injecting drug users
(IDUs) in the area, low retention rate of the MMT clinic indicates that the commu-
nity-based programmight have been suboptimally utilised or else poorlymanaged.
Attaining maintenance phase at a minimum dose of 60 mg was insufficient to
ensure compliance. Health workers should maintain relationships with patients’
family to help support and monitor the treatment. Similar studies in hospital or
correctional institution settings and/or other areas are needed to confirm the find-
ings as well as economic analyses to anticipate waste of resources.
MENTAL HEALTH – Cost Studies
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IMPACT OF REFILL AND SAVE PROGRAM ON ADHERENCE TO DESVENLAFAXINE
AND EXTENDED RELEASE VENLAFAXINE HCL
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OBJECTIVES: Depressive disorders affect 35 million US adults annually. A large
US health plan offers some members a “Refill and Save Program” (RSP), with dis-
counted copayments for desvenlafaxine (DSV) and extended-release venlafaxine
(VENXR) when refilled within 30 days after previous fill run-out. This study com-
pared adherence between RSP and non-RSP cohorts.METHODS: This retrospective
claims database study examined adult commercial members with 1 claim for
DSV or VENXR fromOctober 1, 2009 – March 31, 2010; the first claim date was index
date. Members with schizophrenia were excluded. Members were continuously
enrolled for 6 months pre-index and 9 months post-index. Proportion of days cov-
ered (PDC) on index antidepressant was modeled with ordinary least-squares re-
gression, controlling for index antidepressant, naïve antidepressant use, demo-
graphic and plan characteristics. Subset analysis was conducted on naïve and
continuing index antidepressant users and on subjects with no change in post-
index RSP exposure. RESULTS: The study population included 46,138 members
withmean age 4812 years and 75.3% female, divided between RSP (n28,925) and
non-RSP (n17,213): 21.4% were naïve to their index antidepressants. Mean PDC
was 69% in RSP, 65% in non-RSP (p0.001). Regression results showed PDC was 6.5
percentage points higher (p0.001) in the RSP versus non-RSP cohort. PDC in RSP
cohort was 8.2 percentage points higher (p0.001) among naïve index antidepres-
sant users, and 6.4 percentage points higher (p0.001) among continuing users.
Analyses on those with no change in post-index RSP exposure yielded similar
significant results but with smaller effect. CONCLUSIONS: The RSP cohort, versus
non-RSP, had higher index antidepressant PDC. These results suggest that copay-
ment discounts may have a positive impact on adherence to desvenlafaxine and
extended-release venlafaxine HCl.
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DIFFERENCES IN HEALTH CARE UTILIZATION AND ASSOCIATED COSTS
BETWEEN PATIENTS PRESCRIBED VERSUS NOT PRESCRIBED OPIOIDS DURING
AN INPATIENT OR EMERGENCY DEPARTMENT VISIT
Xie L1, Joshi AV2, Harnett J2, Mardekian J2, Schaaf D2, Shah N3, Baser O1
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Pfizer, Inc., New York,
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OBJECTIVES: Compare health care resource utilization (HCRU) and costs between
patients prescribed opioids versus those who were not during emergency depart-
ment (ED) or inpatient visits. METHODS: Patients with ED/inpatient visits were
selected from the MarketScan Commercial and Medicare Supplemental Database
linked with the Marketscan Hospital Discharge Database (1/12007–9/30/2009). Pa-
tients prescribed opioids in the ED/inpatient setting were assigned to the ‘Opioid
Patient (RxOP)’ cohort. The first prescription date was the index date. Among pa-
tients not prescribed opioids, the ‘Non-Opioid Patient (NoRxOP)’ cohort, a random
date between the first ED/inpatient admission and 30SEPT2009 served as the index
date. Additional inclusion criteria were: age older than 12 years at index date, and
12months of continuous enrollment before and after the index date. Patients with
opioid prescriptions during the pre-index period were excluded. Differences in
patients’ age, gender, geographic region, comorbidities, and HCRU during the pre-
index period were adjusted by 1:1 propensity score (PS) matching (PSM). RESULTS:
Overall, opioids were prescribed in 56% of patients in ED, and 71% in inpatient
setting. After excluding patients with pre-index opioid use (N163), among 27,599
eligible patients, 68% (RxOP: N18,819) were prescribed opioids, and 32% (NoRxOP:
N8,780) were not. The majority of patients (96%, N18,031) were prescribed im-
mediate-release opioids and 4% (N788) extended-release opioids (LAO use
slightly higher in ED versus inpatient, 6.5% versus 3.7%, p0.01). Among the 5099 PS
matched patients, adjusted results showed that RxOP patients had more inpatient
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